Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Income Before Tax

Profit after all operating and non-operating items but before income tax.

Amgen Inc.NASDAQ: AMGN

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax growth accelerates

Q2 FY2026 income before tax of $2.77B rose 76.5% year over year, ahead of the +38.6% change in trailing-twelve-month income before tax. Sequentially, it rose 32.8% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.

Context

  • Income before tax amounted to 24.4% of revenue in FY2025, up 10.6 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +76.5% holds above the trailing-twelve-month pace of +38.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.77B+32.8% QoQ
Last fiscal yearDec 2025
$8.98B+94.7% YoY
LTMJun 2026
$10.29B+38.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+76.5%——
1 year+94.7%——
3-year CAGR+6.9%——
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
8.98B USD
Year-over-year change
+94.7%
4-year CAGR
+7.6%

Income Before Tax vs competitors

How AMGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +38.6% is the 4th highest of 10, against a peer median of +15.8%.
  • Income before tax amounts to 27.0% of revenue for AMGN, versus a peer median of 19.4%.
AMGN Competitors
Income Before Tax for AMGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$33.6B USD+99.3%+55.8%42.2%
JNJJohnson & JohnsonLTM Sep 2026$17.74B USD-43.7%+18.9%17.9%
NVSNovartis AGLTM Jun 2026$15.52B USD-0.5%+31.8%27.9%
AZNAstraZeneca PLCLTM Sep 2026$13.25B USD+15.8%+70.5%21.3%
ABBVAbbVie Inc.LTM Sep 2026$12.81B USD+671.9%-21.2%19.4%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$11.91B USD+80.6%+6.5%24.2%
AMGNAmgen Inc.LTM Jun 2026$10.29B USD+38.6%+6.9%27.0%
MRKMerck & Co., Inc.LTM Jun 2026$5.95B USD-69.0%+8.6%9.0%
GSKGSK plcLTM Jun 2026£5.9B GBP+27.7%+9.6%17.8%
PFEPfizer Inc.LTM Jun 2026$4.21B USD-60.0%-40.0%6.6%
Peer median (excluding AMGN) —+15.8%+9.6%19.4%

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.98B26.32B28.19B33.42B36.74B
Cost of Revenue6.45B6.41B8.42B12.86B10.73B
Gross Profit19.53B19.92B19.78B20.57B26.01B
Gross Margin75.2%75.7%70.1%61.5%70.8%
Research & Development6.32B4.43B4.78B5.96B6.97B
Selling, General & Admin5.37B5.41B6.18B7.1B7.05B
Operating Expenses11.89B10.35B11.84B13.31B15.34B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
EBITDA11.3B12.17B14.8B13.36B16.9B
EBITDA Margin43.5%46.2%52.5%40.0%46.0%
Operating Income7.64B9.57B7.9B7.26B10.68B
Operating Margin29.4%36.3%28.0%21.7%29.1%
Interest Income00000
Interest Expense1.2B1.41B2.88B3.16B2.76B
Other Income / Expenses(938M)(2.22B)(42M)(2.65B)(1.7B)
Income Before Tax6.7B7.35B7.86B4.61B8.98B
Pre-Tax Margin25.8%27.9%27.9%13.8%24.4%
Income Tax Expense808M794M1.14B519M1.27B
Net Income5.89B6.55B6.72B4.09B7.71B
Net Margin22.7%24.9%23.8%12.2%21.0%
EPS (Basic)10.3412.1812.567.6214.33
EPS (Diluted)10.2812.1112.497.5614.23
Weighted Avg Shares570M538M535M541M538M
Weighted Avg Shares (Diluted)573M541M538M541M542M

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.